THYROLAR-5
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-5 is an oral tablet small-molecule product approved by AbbVie in 1969 for thyroid hormone replacement therapy. The drug treats hypothyroidism and related thyroid conditions. Mechanism of action and specific indications are not publicly detailed in this dataset.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand team is likely in transition or consolidation mode rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYROLAR-5 presents limited career growth opportunities given zero linked job postings and approaching loss of exclusivity. Roles available are primarily defensive and cost-management focused rather than growth-oriented, making this a consolidation or legacy product assignment.
Brand ManagerField Sales Representative
Worked on THYROLAR-5 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.